Journal for ImmunoTherapy of Cancer (Nov 2021)

959 Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial

  • Harpreet Singh,
  • Jason Luke,
  • Mamta Kalra,
  • Martin Wermke,
  • Dejka Araujo,
  • Ali Mohamed,
  • Winfried Alsdorf,
  • Apostolia-Maria Tsimberidou,
  • Andrea Mayer-Mokler,
  • Arun Satelli,
  • Carsten Reinhardt,
  • Dominik Maurer,
  • George Jr Blumenschein,
  • Kerstin Guenther,
  • Manik Chatterjee,
  • Norbert Hilf,
  • Regina Mendrzyk,
  • Steffen Walter,
  • Stephen Eck,
  • Tobias AW Holderried,
  • Toni Weinschenk,
  • Van Morris,
  • Cedrik M Britten

DOI
https://doi.org/10.1136/jitc-2021-SITC2021.959
Journal volume & issue
Vol. 9, no. Suppl 2

Abstract

Read online

No abstracts available.